Key Points
- COO Kathleen Goin sold 4,302 shares of Palvella on Dec. 17 at an average price of $96.47 for $415,013.94 (she also sold 4,302 shares on Nov. 19 at $86.23); the transaction was disclosed in an SEC filing.
- Wall Street sentiment is largely bullish with multiple firms raising price targets (Oppenheimer to $200, Truist to $190, Craig Hallum $175) and a consensus "Buy" rating with an average target of $155.60.
- Palvella shares opened at $99.73 and trade well above their 200‑day moving average ($57.18) but the company recently missed quarterly EPS estimates (reported ($1.03) vs. ($0.85) expected) and remains unprofitable.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Kathleen Goin also recently made the following trade(s):
- On Wednesday, November 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $86.23, for a total value of $370,961.46.
Palvella Therapeutics Price Performance
Shares of Palvella Therapeutics stock opened at $99.73 on Friday. The stock's 50-day moving average is $85.80 and its 200 day moving average is $57.18. Palvella Therapeutics, Inc. has a one year low of $11.17 and a one year high of $112.00. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -37.92 and a beta of -0.20.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.18). On average, sell-side analysts expect that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on PVLA shares. Truist Financial boosted their price target on shares of Palvella Therapeutics from $105.00 to $190.00 and gave the stock a "buy" rating in a report on Monday. Craig Hallum assumed coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They issued a "buy" rating and a $175.00 price objective on the stock. Weiss Ratings reissued a "sell (d)" rating on shares of Palvella Therapeutics in a research report on Monday. UBS Group restated a "buy" rating and set a $143.00 price target on shares of Palvella Therapeutics in a research note on Monday. Finally, Chardan Capital lifted their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the company a "buy" rating in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $155.60.
Read Our Latest Report on Palvella Therapeutics
Institutional Trading of Palvella Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of PVLA. Archer Investment Corp purchased a new position in Palvella Therapeutics in the 3rd quarter worth approximately $28,000. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics in the 3rd quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Palvella Therapeutics in the second quarter worth approximately $37,000. JPMorgan Chase & Co. boosted its stake in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company's stock worth $73,000 after buying an additional 3,242 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Palvella Therapeutics during the second quarter valued at approximately $85,000. 40.11% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting Palvella Therapeutics
Here are the key news stories impacting Palvella Therapeutics this week:
- Positive Sentiment: Oppenheimer raised its price target to $200 from $120, a strong signal from a sell‑side firm that can boost bullish interest. Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer
- Positive Sentiment: TD Cowen raised its price target to $133, adding further upward pressure on the stock via another institutional endorsement. TD Cowen Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $133.00
- Positive Sentiment: Market headlines note an analyst upgrade that coincided with a recent sharp move higher in PVLA shares, which likely amplified buying momentum. Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 6.6% After Analyst Upgrade
- Neutral Sentiment: HC Wainwright revised down near‑term EPS forecasts for FY2027–FY2029 (multiple cuts) but kept a "Buy" rating and a $200 price target — a mixed signal that tempers long‑term optimism with weaker near‑term profitability projections.
- Negative Sentiment: Lifesci Capital cut its FY2026 EPS estimate (worse expected losses), a negative revision that could weigh on sentiment if the company misses near‑term expectations.
- Negative Sentiment: COO Kathleen Goin sold 4,302 shares at an average price of $96.47 (SEC filing), a disclosure investors often view as a cautionary sign even if the sale may be for personal reasons. SEC filing
About Palvella Therapeutics
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
